Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 4/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022483 | 0.89 | TSHR (0.33) | PRKCITSHRGCGR | |
| SCHEMBL1842928 | 0.89 | TSHR (0.36) | PRKCITYRTSHRGCGR | |
| SCHEMBL2018232 | 0.89 | TYR (0.43) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL2018205 | 0.81 | TSHR (0.39) | PRKCIALOX5TSHRHTTGCGR | |
| SCHEMBL2020815 | 0.81 | TSHR (0.46) | PRKCITYRALOX5MEN1TP53 | |
| SCHEMBL1842265 | 0.79 | TSHR (0.38) | TSHRGCGR | |
| SCHEMBL2018905 | 0.79 | ALOX15 (0.32) | ALOX15 | |
| SCHEMBL2019389 | 0.78 | TYR (0.38) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL1841110 | 0.78 | TYR (0.41) | TYRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL2025171 | 0.77 | TYR (0.40) | TYRALOX5MEN1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | PRKCI 698/4885TYR 886/4885ALOX5 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.